These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 1717712)

  • 1. A predominant group-specific neutralizing epitope of human immunodeficiency virus type 1 maps to residues 342 to 511 of the envelope glycoprotein gp120.
    Berkower I; Murphy D; Smith CC; Smith GE
    J Virol; 1991 Nov; 65(11):5983-90. PubMed ID: 1717712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope protein.
    Javaherian K; Langlois AJ; Montefiori DC; Kent KA; Ryan KA; Wyman PD; Stott J; Bolognesi DP; Murphey-Corb M; Larosa GJ
    J Virol; 1994 Apr; 68(4):2624-31. PubMed ID: 7511176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.
    Nakamura GR; Byrn R; Wilkes DM; Fox JA; Hobbs MR; Hastings R; Wessling HC; Norcross MA; Fendly BM; Berman PW
    J Virol; 1993 Oct; 67(10):6179-91. PubMed ID: 7690420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
    Roben P; Moore JP; Thali M; Sodroski J; Barbas CF; Burton DR
    J Virol; 1994 Aug; 68(8):4821-8. PubMed ID: 7518527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralization epitopes of the HIV-1 primary isolate DH012.
    Zhu C; Matthews TJ; Chen CH
    Vaccine; 2003 Jul; 21(23):3301-6. PubMed ID: 12804861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody.
    Ho DD; McKeating JA; Li XL; Moudgil T; Daar ES; Sun NC; Robinson JE
    J Virol; 1991 Jan; 65(1):489-93. PubMed ID: 1702163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120.
    Kang CY; Hariharan K; Nara PL; Sodroski J; Moore JP
    J Virol; 1994 Sep; 68(9):5854-62. PubMed ID: 7520095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans.
    Moore JP; Ho DD
    J Virol; 1993 Feb; 67(2):863-75. PubMed ID: 7678308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region.
    Wyatt R; Thali M; Tilley S; Pinter A; Posner M; Ho D; Robinson J; Sodroski J
    J Virol; 1992 Dec; 66(12):6997-7004. PubMed ID: 1279195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alteration of V3 loop context within the envelope of human immunodeficiency virus type 1 enhances neutralization.
    Robert-Guroff M; Louie A; Myagkikh M; Michaels F; Kieny MP; White-Scharf ME; Potts B; Grogg D; Reitz MS
    J Virol; 1994 Jun; 68(6):3459-66. PubMed ID: 7514675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain.
    Wu L; Zhou T; Yang ZY; Svehla K; O'Dell S; Louder MK; Xu L; Mascola JR; Burton DR; Hoxie JA; Doms RW; Kwong PD; Nabel GJ
    J Virol; 2009 May; 83(10):5077-86. PubMed ID: 19264769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response.
    Bolmstedt A; Sjölander S; Hansen JE; Akerblom L; Hemming A; Hu SL; Morein B; Olofsson S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jul; 12(3):213-20. PubMed ID: 8673525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The V3 domain of SIVmac251 gp120 contains a linear neutralizing epitope.
    Palker TJ; Muir AJ; Spragion DE; Staats HF; Langlois A; Montefiori DC
    Virology; 1996 Oct; 224(2):415-26. PubMed ID: 8874502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120.
    Pan R; Qin Y; Banasik M; Lees W; Shepherd AJ; Cho MW; Kong XP
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29343576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antigenic structure of the HIV gp120 envelope glycoprotein.
    Wyatt R; Kwong PD; Desjardins E; Sweet RW; Robinson J; Hendrickson WA; Sodroski JG
    Nature; 1998 Jun; 393(6686):705-11. PubMed ID: 9641684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1.
    Javaherian K; Langlois AJ; Schmidt S; Kaufmann M; Cates N; Langedijk JP; Meloen RH; Desrosiers RC; Burns DP; Bolognesi DP
    Proc Natl Acad Sci U S A; 1992 Feb; 89(4):1418-22. PubMed ID: 1371358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An unrelated monoclonal antibody neutralizes human immunodeficiency virus type 1 by binding to an artificial epitope engineered in a functionally neutral region of the viral envelope glycoproteins.
    Ren X; Sodroski J; Yang X
    J Virol; 2005 May; 79(9):5616-24. PubMed ID: 15827176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120.
    McKeating JA; Cordell J; Dean CJ; Balfe P
    Virology; 1992 Dec; 191(2):732-42. PubMed ID: 1280382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeys.
    Etemad-Moghadam B; Karlsson GB; Halloran M; Sun Y; Schenten D; Fernandes M; Letvin NL; Sodroski J
    J Virol; 1998 Oct; 72(10):8437-45. PubMed ID: 9733899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.